Cargando…

Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

BACKGROUND: Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Legge, Francesco, Paglia, Amelia, D'Asta, Marco, Fuoco, Gilda, Scambia, Giovanni, Ferrandina, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123659/ https://www.ncbi.nlm.nih.gov/pubmed/21627839 http://dx.doi.org/10.1186/1471-2407-11-214

Ejemplares similares

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
por: Ferrandina, Gabriella, et al.
Publicado: (2014)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report
por: Corrado, Giacomo, et al.
Publicado: (2010)

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
por: Sharma, R, et al.
Publicado: (2009)

Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
por: Legge, Francesco, et al.
Publicado: (2008)

Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis
por: Mantegna, Giovanna, et al.
Publicado: (2013)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
por: Pignata, S, et al.
Publicado: (2007)

Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
por: Cappuccio, Serena, et al.
Publicado: (2020)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
por: Sharma, Sanjay, et al.
Publicado: (2003)

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2015)

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
por: McMeekin, S, et al.
Publicado: (2012)

Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters
por: Ferrandina, G, et al.
Publicado: (2005)

Adrenomedullin in Ovarian Cancer: Foe In Vitro and Friend In Vivo?
por: Baranello, Cinzia, et al.
Publicado: (2012)

Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

MiR-200c and HuR in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2013)

Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial
por: Ferrandina, G, et al.
Publicado: (2009)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
por: Allen, Valerie A., et al.
Publicado: (2016)

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
por: Chekerov, Radoslav, et al.
Publicado: (2017)

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
por: Martin, Jovana Y., et al.
Publicado: (2016)

The role of apparent diffusion coefficient (ADC) in the evaluation of lymph node status in patients with locally advanced cervical cancer: our experience and a review
por: Gui, Benedetta, et al.
Publicado: (2022)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature
por: Turco, Luigi Carlo, et al.
Publicado: (2020)

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
por: Lv, Xing, et al.
Publicado: (2016)

Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature
por: Masciullo, V., et al.
Publicado: (2010)

Conservatively treated glassy cell carcinoma of the cervix
por: Ferrandina, Gabriella, et al.
Publicado: (2008)

Femur metastasis in carcinoma of the uterine cervix: a rare entity
por: Corrado, Giacomo, et al.
Publicado: (2009)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)

Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series
por: De Ioris, Maria Antonietta, et al.
Publicado: (2023)

Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
por: Ikeda, Naoya, et al.
Publicado: (2022)

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
por: Pignata, Sandro, et al.
Publicado: (2006)

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
por: Colombo, Nicoletta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lg1k4329n0duolvf955oj0ubsm